British drugs giant GlaxoSmithKline closes 9.8bn deal with US rival Pfizer to merge healthcare business in bid to cut 500m costs and split firm in two
The 9.8billion deal will see UK-based GSK get 68 per cent equity and Pfizer the remaining 32 per cent in the hope of cutting 500million in costs by 2022.
